Is LGND research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LGND. It does not provide personalized investment advice.

LGND (Ligand Pharmaceuticals Inc.) Stock Analysis - Financials

Ligand Pharmaceuticals Inc. (LGND) is a publicly traded Healthcare sector company. As of October 27, 2026, LGND trades at $311.82 with a market cap of $6.15B and a P/E ratio of 28.86. LGND moved +1.44% today. Year to date, LGND is +63.97%; over the trailing twelve months it is +64.09%. Its 52-week range spans $93.58 to $326.63. Analyst consensus is strong buy with an average price target of $362.83. Rallies surfaces LGND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are LGND's key financials?

LGND financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LGND recently traded at $311.82. Market cap is $6.15B. P/E ratio is 28.86. Revenue is $290.54M.

LGND Key Metrics

Key financial metrics for LGND
Metric	Value
Price	$311.82
Market Cap	$6.15B
P/E Ratio	28.86
EPS	$10.07
Dividend Yield	0.08%
52-Week High	$326.63
52-Week Low	$93.58
Volume	105.02K
Avg Volume	0
Revenue (TTM)	$290.54M
Net Income	$197.22M
Gross Margin	0.00%

LGND Analyst Consensus

8 analysts cover LGND: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $362.83.

Common questions about LGND

What are LGND's key financials?: LGND financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LGND recently traded at $311.82. Market cap is $6.15B. P/E ratio is 28.86. Revenue is $290.54M.
Is LGND research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LGND. It does not provide personalized investment advice.